focus
LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.
The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.
advertisement
AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
5 takeaways from STAT's examination of Zynex Medical
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
